Korro Bio (KRRO) Stock Price, News & Analysis

Company Overview

Korro Bio, Inc. is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics. Lead candidate KB103 is an investigational enzyme replacement therapy designed to address congenital hyperbilirubinemia by restoring deficient UGT1A1 activity. In parallel, Korro Bio is advancing a portfolio of live microbial drug candidates aimed at modulating the human microbiome to treat unmet medical needs in gastroenterology and oncology. These programs reflect the company’s dual focus on systemic enzyme therapies and targeted microbial approaches.

Founded in 2019 and headquartered in Boston, Massachusetts, Korro Bio completed its initial public offering on the Nasdaq under the ticker KRRO in late 2021. The company collaborates with leading academic and industry partners to expand its enzyme discovery platform and accelerate translational research. Led by an experienced management team with backgrounds in biotherapeutics, protein science and drug development, Korro Bio serves a global pharmaceutical customer base and is committed to advancing innovative treatments from bench to bedside.

Key Stats

• Today's Range: $26.71 to $34.74
• 50-Day Range: $12.49 to $33.18
• 52-Week Range: $10.29 to $98.00
• Volume: 1.01 million shs
• Average Volume: 168,762 shs
• Market Capitalization: $311.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $86.83
• Consensus Rating: Buy

Korro Bio Stock Analysis - MarketRank™

Korro Bio scored higher than 42% of companies evaluated by MarketBeat, and ranked 703rd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Buy

Consensus Rating

Korro Bio has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Korro Bio has a consensus price target of $86.83, representing about 161.7% upside from its current price of $33.18.

Amount of Analyst Coverage

Korro Bio has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Korro Bio are expected to decrease in the coming year, from ($9.52) to ($10.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Korro Bio is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Korro Bio is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Korro Bio has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.53% of the float of Korro Bio has been sold short.

Short Interest Ratio / Days to Cover

Korro Bio has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Korro Bio has recently increased by 4.20%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Korro Bio does not currently pay a dividend.

Dividend Growth

Korro Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

23.53% of the float of Korro Bio has been sold short.

Short Interest Ratio / Days to Cover

Korro Bio has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Korro Bio has recently increased by 4.20%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.45

News Sentiment

Korro Bio has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Korro Bio this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for KRRO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Korro Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.60% of the stock of Korro Bio is held by insiders.

Percentage Held by Institutions

Only 13.18% of the stock of Korro Bio is held by institutions.

KRRO Stock Analysis - Frequently Asked Questions

How have KRRO shares performed this year?

Korro Bio's stock was trading at $38.07 at the beginning of 2025. Since then, KRRO shares have decreased by 12.8% and is now trading at $33.18.

How were Korro Bio's earnings last quarter?

Korro Bio, Inc. (NASDAQ:KRRO) announced its quarterly earnings results on Tuesday, August, 12th. The company reported ($2.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.54) by $0.20. The firm had revenue of $1.46 million for the quarter, compared to analyst estimates of $0.41 million.

Who are Korro Bio's major shareholders?

Top institutional shareholders of Korro Bio include Geode Capital Management LLC (1.65%), Raymond James Financial Inc. (0.89%), Bank of America Corp DE (0.30%) and AlphaQuest LLC (0.29%). Insiders that own company stock include Venture Opportunity Fund Atlas, David L Lucchino and Vineet Agarwal.
View institutional ownership trends.

How do I buy shares of Korro Bio?

Shares of KRRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Korro Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Korro Bio investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/06/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KRRO
• Previous Symbol: NASDAQ:KRRO
• CIK: 1703647
• Web: www.frequencytx.com
• Phone: 781-315-4600
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Korro Bio: $86.83
• High Price Target: $147.00
• Low Price Target: $25.00
• Potential Upside/Downside: +161.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$83.58 million
• Net Margins: N/A
• Pretax Margin: -1,452.95%
• Return on Equity: -61.51%
• Return on Assets: -42.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.98
• Quick Ratio: 5.98

Sales & Book Value

• Annual Sales: $2.27 million
• Price / Sales: 137.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $17.12 per share
• Price / Book: 1.94

Miscellaneous

• Outstanding Shares: 9,390,000
• Free Float: 8,959,000
• Market Cap: $311.56 million
• Optionable: No Data
• Beta: 2.66